IOL Chemicals & Pharmaceuticals reported a strong Q2 FY27, with revenue rising 40% to ₹795 crore and profit surging 116% to ₹65 crore. The company announced a ₹495 crore strategic expansion plan covering Ibuprofen capacity, CDMO, and specialty chemicals, funded through internal accruals.
IOL Chemicals Q2 Net Profit Climbs 116% To ₹65 Crore
Revenue for the quarter grew 40.1% YoY to ₹795 crore, while EBITDA margin improved significantly.
Reader Takeaway: Robust profit growth fueled by core operations, while upcoming ₹495 crore capex marks a shift toward diversification.
What just happened
IOL Chemicals & Pharmaceuticals (IOLCP) released its financial results for Q2 and H1 FY27, reporting substantial growth across all key metrics. Net profit for Q2 FY27 rose to ₹65 crore, compared to ₹30 crore in the same period last year. Revenue stood at ₹795 crore, a 40.1% increase over Q2 FY26. The company also unveiled a capital expenditure plan of ₹495 crore to be deployed across three strategic areas.
Why this matters
The significant jump in profitability indicates improved operational efficiency and a stronger product mix. The strategic pivot toward a broader portfolio is highlighted by the non-Ibuprofen API business, which now accounts for 44% of H1 FY27 revenue, up from 18% in FY21. The decision to fund the entire ₹495 crore capex through internal accruals highlights a healthy balance sheet and disciplined financial management.
Strategic Initiatives
The company's growth roadmap involves three distinct projects:
- Ibuprofen Expansion: ₹350 crore investment to add 6,000 MTPA capacity, targeting FY28 commercialization.
- CDMO Entry: A ₹110 crore foray into pharmaceutical formulations, expected to be operational by FY27.
- Specialty Chemicals: A ₹35 crore investment in a dedicated facility under a long-term tolling agreement, expected online by FY27.
Risks to watch
Execution remains the primary monitorable. Shareholders should track the commissioning timelines for the CDMO and specialty chemical projects, as delays could impact growth guidance. Additionally, the company faces exposure to global API price volatility and competitive pressures in the chemical segment.
What to track next
Investors should monitor quarterly progress updates on the capex project implementation. Management has provided guidance for 25%+ revenue growth for FY26-27, which will be a key metric to observe in the coming quarters.